Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it

Thirty-six percent of employers cover GLP-1 drugs for weight loss and diabetes, according to CNBC—unchanged from twenty twenty-five, suggesting limited momentum toward expanded access.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton